Synthetic Biologics (SYN) Seen as Undervalued at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
Synthetic Biologics (SYN) Announces Second SYN-010 Phase 2 in IBS-C Met Primary Endpoint
January 19, 2016 4:35 PM ESTSynthetic Biologics, Inc. (NYSE: SYN) reported that the second Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C) met its primary... More
